Cargando…

Drug discovery in the p53 pathway

Detalles Bibliográficos
Autores principales:	Lane, DP, Midgley, C, Sparks, A, Blattner, C, Binden, C, Laine, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2000
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3300836/ http://dx.doi.org/10.1186/bcr137

Ejemplares similares

p53 action in apoptosis and senescence
por: Lowe, SW, et al.
Publicado: (2000)

Inflammation, senescence and cancer: interweaving microRNA, inflammatory cytokines and p53 networks
por: Harris, Curtis C
Publicado: (2010)

TP53 and additional pathways in therapy resistance
por: Lønning, PE
Publicado: (2005)

p53-mediated apoptosis and genomic instability syndromes
por: Spillare, EA, et al.
Publicado: (2000)

Role of animal models in oncology drug discovery
por: Kumar, R
Publicado: (2003)

Towards a patient-based drug discovery
por: Schreiber, Stuart L
Publicado: (2012)

The role of systems modeling in drug discovery and predictive health
por: Voit, Eberhard O
Publicado: (2010)

Evading p53 action during tumor development and therapy
por: Lowe, SW
Publicado: (2005)

Natural product-likeness score and its applications in the drug discovery process
por: Ertl, Peter, et al.
Publicado: (2008)

Genomic approaches to drug target discovery using mouse models
por: Morris, DW
Publicado: (2003)

Genetically modified cancer models: the value of luciferase-tagged tumors and in vivo luciferase-based reporter assays in oncology drug discovery
por: Yang, W, et al.
Publicado: (2003)

Antimalarial drug discovery: targeting the hypnozoite for new radical curative agent
por: Yeung, Bryan
Publicado: (2012)

Apoptosis factors caspases and p53 and their impact in chronic rhinosinusitis with nasal polyposis
por: Valera, Fabiana, et al.
Publicado: (2013)

OA01.46. Effect of LAS-02, a cancero-static compound on p53 levels in cases of different types of cancers
por: Singh, Vandana, et al.
Publicado: (2012)

CADDSuite – a workflow-enabled suite of open-source tools for drug discovery
por: Kohlbacher, Oliver
Publicado: (2012)

Activation of CDK4 by Tax chemosensitizes p53-mutant cells to DNA damage
por: Semmes, O John, et al.
Publicado: (2014)

T cells are depleted in HCV-induced hepatocellular carcinoma patients: possible role of apoptosis and p53
por: Ibrahim, Sherif A, et al.
Publicado: (2006)

OA02.08. Chick embryo model an experimental model for drug discovery in ayurveda.
por: Tomar, Ekta, et al.
Publicado: (2013)

Autophagy turns specific: the discovery of p62 and NBR1 as autophagy cargo receptors
por: Bjørkøy, Geir
Publicado: (2010)

Pluripotent stem cells for pathological modelling of Hutchinson-Gilford Progeria Syndrome (HGPS) and drug discovery
por: Nissan, Xavier
Publicado: (2015)

S9.3d Antivirulence drug discovery to disarm Candida albicans with metabolites from myxobacteria.
por: Vij, Raghav, et al.
Publicado: (2022)

Estrogen receptor alpha-positive and negative mouse mammary tumors through somatic mutations of p53 in mammary carcinogenesis
por: Lin, S-CJ, et al.
Publicado: (2003)

Target discovery in the postgenomic era
por: Friedman, L, et al.
Publicado: (2003)

O045 Sleep management strategies among medical students
por: Duthie, C, et al.
Publicado: (2022)

DNA repair and breast cancer: therapeutic opportunities
por: Silver, DP
Publicado: (2011)

A new P. falciparum gametocyte drug screening assay based on pLDH detection
por: D’Alessandro, Sarah, et al.
Publicado: (2012)

Ion channels: their discovery, their function, and their role in disease
por: Neher, Erwin
Publicado: (2014)

S5.3b Fungal spores: Initiators of colonization and infection
por: Baltussen, Tim, et al.
Publicado: (2022)

P045 The association of performance of air pollutants on Candida drug resistance
por: Ghazanfari, Sahar, et al.
Publicado: (2022)

Discovery of stat3 signalling and its clinical relevance
por: Horn, Friedemann
Publicado: (2011)

SNP discovery and association mapping in Eucalyptus pilularis (blackbutt)
por: Sexton, Timothy, et al.
Publicado: (2011)

S5.3c Investigating the link between pleomorphism and virulence in Cryptococcus
por: Fernandes, Kenya, et al.
Publicado: (2022)

S5.3a Unraveling the genetic determinants of virulence in Cryptococcus neoformans
por: Jackson, Katrina, et al.
Publicado: (2022)

Targeting protein dynamics in drug design
por: Wade, Rebecca C
Publicado: (2013)

IFN-α suppresses HTLV-1 expression via PKR in infected cells and renders them susceptible to AZT through p53 activation in AZT/IFN-α treatment
por: Kinpara, Shuichi, et al.
Publicado: (2014)

A single nucleotide polymorphism in the HDM-2 gene regulates the p53 apoptotic response and influences the age of onset of cancers in humans: the SNP 309 HDM-2 polymorphism
por: Bond, GL, et al.
Publicado: (2005)

P189 The effect of COVID-19 and immunosuppressive drugs and diabetes on the spread of mucomycosis
por: Esfidani, Maryam
Publicado: (2022)

S101: COMBINATION OF A LUSPATERCEPT-LIKE DRUG (RAP-GRL) AND TMPRSS6-ASO IS SUPERIOR TO EITHER DRUG ALONE FOR CORRECTING β-THALASSEMIA
por: Guerra, A., et al.
Publicado: (2022)

Integrating automated literature searches and text mining in biomarker discovery
por: Ongenaert, Maté, et al.
Publicado: (2010)

P024 Genetic determinants of antifungal drug resistance in Fusarium solani species complex
por: Trivedi, Pinal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p6qbtkvdgm5asb873puc97b7ra